Aurinia Pharmaceuticals (AUPH) EBIT Margin (2019 - 2026)
Aurinia Pharmaceuticals (AUPH) reported EBIT Margin of 53.31% for Q1 2026, up 1833.0% on a YoY basis from 2.76% in Q1 2025, and up 23.67% quarter-over-quarter from 43.1% in Q4 2025.
Aurinia Pharmaceuticals (AUPH) EBIT Margin (2019 - 2026) Analysis & Trends
Aurinia Pharmaceuticals has reported EBIT Margin for 8 years, with the latest figure at 53.31% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin rose 1833.0% year-over-year to 53.31%; the trailing twelve-month figure through Mar 2026 stood at 41.73% (up 2944.0% YoY), and the FY2025 full-year result was 37.06%, up 3906.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 53.31%, up from 43.1% in the prior quarter.
- The five-year high for EBIT Margin was 53.31% in Q1 2026, with the low at 175.18% in Q1 2022.
- Historically, EBIT Margin has averaged 26.66% across 5 years, with a median of 17.03% in 2022.
- Annual changes were most pronounced in 2022 — EBIT Margin soared 535469 bps — and 2023, when it tumbled 1280 bps.
- Aurinia Pharmaceuticals' EBIT Margin stood at 98.82% in 2022, then surged by 33 bps to 65.8% in 2023, then surged by 96 bps to 2.79% in 2024, then soared by 1646 bps to 43.1% in 2025, then gained by 24 bps to 53.31% in 2026.
- The last three EBIT Margin figures came in at 53.31% (Q1 2026), 43.1% (Q4 2025), and 40.49% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Aurinia Pharmaceuticals | 2.18 Bn | 1.80 Bn | 71.20 Mn | 53.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.31% |
| Dec 31, 2025 | 43.10% |
| Sep 30, 2025 | 40.49% |
| Jun 30, 2025 | 28.69% |
| Mar 31, 2025 | 34.97% |
| Dec 31, 2024 | -2.79% |
| Sep 30, 2024 | 17.33% |
| Jun 30, 2024 | -2.65% |
| Mar 31, 2024 | -26.35% |
| Dec 31, 2023 | -65.80% |
| Sep 30, 2023 | -29.83% |
| Jun 30, 2023 | -38.97% |
| Mar 31, 2023 | -85.98% |
| Dec 31, 2022 | -98.82% |
| Sep 30, 2022 | -17.03% |
| Jun 30, 2022 | -127.66% |
| Mar 31, 2022 | -175.18% |
| Dec 31, 2021 | -139.74% |
| Sep 30, 2021 | -343.31% |
| Jun 30, 2021 | -711.99% |